{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:03:54Z","timestamp":1783469034594,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40262-018-0641-x","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T23:41:38Z","timestamp":1521762098000},"page":"1217-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3245-1626","authenticated-orcid":false,"given":"S\u00edlvia M.","family":"Illamola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-3207","authenticated-orcid":false,"given":"Catherine M.","family":"Sherwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-7314","authenticated-orcid":false,"given":"J. G. Coen","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"key":"641_CR1","unstructured":"Boehr DD, Draker KA, Wright GD. Aminoglycoside and aminocyclitols. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, editors. Antibiotic and chemotherapy: anti-infective agents and their use in therapy. New York: Churchill Livingstone; 2003. pp. 155\u201384."},{"issue":"1","key":"641_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clp.2010.01.016","volume":"37","author":"AR Spitzer","year":"2010","unstructured":"Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps\u00ae Data Warehouse and the Pediatrix QualitySteps Improvement Project System\u2013tools for \u201cmeaningful use\u201d in continuous quality improvement. Clin Perinatol. 2010;37(1):49\u201370. \n                    https:\/\/doi.org\/10.1016\/j.clp.2010.01.016\n                    \n                  .","journal-title":"Clin Perinatol"},{"key":"641_CR3","unstructured":"BMS. Amikacin. Summary of product characteristics. Princeton, NJ: BMS; 2014."},{"issue":"11","key":"641_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ppul.22813","volume":"48","author":"DC Young","year":"2013","unstructured":"Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol. 2013;48(11):1047\u201361. \n                    https:\/\/doi.org\/10.1002\/ppul.22813\n                    \n                  .","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"641_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-16.4.262","volume":"16","author":"WA Prescott Jr","year":"2011","unstructured":"Prescott WA Jr. National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther. 2011;16(4):262\u20139. \n                    https:\/\/doi.org\/10.5863\/1551-6776-16.4.262\n                    \n                  .","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"641_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijantimicag.2013.11.006","volume":"43","author":"KJ Downes","year":"2014","unstructured":"Downes KJ, Hahn A, Wiles J, Courter JD, Vinks AA. Dose optimisation of antibiotics in children: application of pharmacokinetics\/pharmacodynamics in paediatrics. Int J Antimicrob Agents. 2014;43(3):223\u201330. \n                    https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.11.006\n                    \n                  .","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"641_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/ACO.0b013e32832bc7ff","volume":"22","author":"A Sumpter","year":"2009","unstructured":"Sumpter A, Anderson BJ. Pediatric pharmacology in the first year of life. Curr Opin Anesthesiol. 2009;22(4):469\u201375. \n                    https:\/\/doi.org\/10.1097\/ACO.0b013e32832bc7ff\n                    \n                  .","journal-title":"Curr Opin Anesthesiol"},{"key":"641_CR8","unstructured":"Zaske D. Applied pharmacokinetics. Principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics; 1992."},{"key":"641_CR9","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ejps.2017.05.022","volume":"109S","author":"EHJ Krekels","year":"2017","unstructured":"Krekels EHJ, van Hasselt JC, van den Ander JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109S:S22\u20136. \n                    https:\/\/doi.org\/10.1016\/j.ejps.2017.05.022\n                    \n                  .","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"641_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1128\/AAC.46.5.1381-1387.2002","volume":"46","author":"JM Treluyer","year":"2002","unstructured":"Treluyer JM, Merle Y, Tonnelier S, Rey E, Pons G. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002;46(5):1381\u20137. \n                    https:\/\/doi.org\/10.1128\/Aac.46.5.1381-1387.2002\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"641_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000047133","volume":"80","author":"JM Labaune","year":"2001","unstructured":"Labaune JM, Bleyzac N, Maire P, Jelliffe RW, Boutroy MJ, Aulagner G, et al. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate. 2001;80(2):142\u20137. \n                    https:\/\/doi.org\/10.1159\/000047133\n                    \n                  .","journal-title":"Biol Neonate"},{"issue":"11","key":"641_CR12","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2215\/CJN.02230409","volume":"4","author":"MF Schreuder","year":"2009","unstructured":"Schreuder MF, Wilhelm AJ, Bokenkamp A, Timmermans SMH, Delemaxre-van de Waal HA, van Wijk JAE. Impact of gestational age and birth weight on amikacin clearance on day 1 of life. Clin J Am Soc Nephrol. 2009;4(11):1774\u20138. \n                    https:\/\/doi.org\/10.2215\/Cjn.02230409\n                    \n                  .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"641_CR13","first-page":"954","volume":"21","author":"J Wang","year":"2000","unstructured":"Wang J, Liang WQ, Wu JJ, Pan CM. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method. Acta Pharmacol Sin. 2000;21(10):954\u201360.","journal-title":"Acta Pharmacol Sin."},{"issue":"3\u20134","key":"641_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000457558","volume":"20","author":"EM Padovani","year":"1993","unstructured":"Padovani EM, Pistolesi C, Fanos V, Messori A, Martini N. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Therap. 1993;20(3\u20134):167\u201373.","journal-title":"Dev Pharmacol Therap"},{"issue":"5","key":"641_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.2042-3306.1994.tb04405.x","volume":"26","author":"MR Golenz","year":"1994","unstructured":"Golenz MR, Wilson WD, Carlson GP, Craychee TJ, Mihalyi JE, Knox L. Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3-day-old and 5-day-old foals. Equine Vet J. 1994;26(5):367\u201373.","journal-title":"Equine Vet J"},{"issue":"4","key":"641_CR16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000480581","volume":"16","author":"PO Petersen","year":"1991","unstructured":"Petersen PO, Wells TG, Kearns GL. Amikacin dosing in neonates - evaluation of a dosing chart based on population pharmacokinetic data. Dev Pharmacol Ther. 1991;16(4):203\u201311.","journal-title":"Dev Pharmacol Ther"},{"issue":"10","key":"641_CR17","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1128\/AAC.01157-15","volume":"59","author":"A Smits","year":"2015","unstructured":"Smits A, De Cock RFW, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CAJ. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344\u201351. \n                    https:\/\/doi.org\/10.1128\/Aac.01157-15\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"641_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40262-013-0101-6","volume":"52","author":"W Zhao","year":"2013","unstructured":"Zhao W, Biran V, Jacqz-Aigrain E. Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates. Clin Pharmacokinet. 2013;52(12):1127\u201334. \n                    https:\/\/doi.org\/10.1007\/s40262-013-0101-6\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"641_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2125.2005.02530.x","volume":"61","author":"K Allegaert","year":"2006","unstructured":"Allegaert K, Anderson BJ, Cossey V, Holford NHG. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol. 2006;61(1):39\u201348. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02530.x\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"641_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.burns.2013.06.015","volume":"40","author":"CMT Sherwin","year":"2014","unstructured":"Sherwin CMT, Wead S, Stockmann C, Healy D, Spigarelli MG, Neely A, et al. Amikacin population pharmacokinetics among paediatric burn patients. Burns. 2014;40(2):311\u20138. \n                    https:\/\/doi.org\/10.1016\/j.burns.2013.06.015\n                    \n                  .","journal-title":"Burns"},{"issue":"7","key":"641_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00228-009-0637-4","volume":"65","author":"CM Sherwin","year":"2009","unstructured":"Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualised dosing of amikacin in neonates: a pharmacokinetic\/pharmacodynamic analysis. Eur J Clin Pharmacol. 2009;65(7):705\u201313. \n                    https:\/\/doi.org\/10.1007\/s00228-009-0637-4\n                    \n                  .","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"641_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/11595640-000000000-00000","volume":"51","author":"RFW Cock De","year":"2012","unstructured":"De Cock RFW, Allegaert K, Schreuder MF, Sherwin CMT, de Hoog M, van den Anker JN, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105\u201317.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"641_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s002280050389","volume":"53","author":"JH Botha","year":"1998","unstructured":"Botha JH, du Preez M, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol. 1998;53(5):337\u201341. \n                    https:\/\/doi.org\/10.1007\/s002280050389\n                    \n                  .","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"641_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2174\/187231208786734157","volume":"2","author":"K Allegaert","year":"2008","unstructured":"Allegaert K, Scheers I, Cossey V, Anderson BJ. Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. Drug Metab Lett. 2008;2(4):286\u20139.","journal-title":"Drug Metab Lett"},{"issue":"3","key":"641_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bcp.13016","volume":"82","author":"SM Illamola","year":"2016","unstructured":"Illamola SM, Colom H, van Hasselt JGC. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol. 2016;82(3):793\u2013805. \n                    https:\/\/doi.org\/10.1111\/bcp.13016\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"641_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/BF01113502","volume":"21","author":"MO Karlsson","year":"1993","unstructured":"Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21(6):735\u201350.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"641_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"THT Nguyen","year":"2017","unstructured":"Nguyen THT, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):87\u2013109. \n                    https:\/\/doi.org\/10.1002\/psp4.12161\n                    \n                  .","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"641_CR28","doi-asserted-by":"publisher","first-page":"E244","DOI":"10.1097\/BCR.0000000000000159","volume":"36","author":"T Yu","year":"2015","unstructured":"Yu T, Stockmann C, Healy DP, Olson J, Wead S, Neely AN, et al. Determination of optimal amikacin dosing regimens for pediatric patients with burn wound sepsis. J Burn Care Res. 2015;36(4):E244\u201352. \n                    https:\/\/doi.org\/10.1097\/Bcr.0000000000000159\n                    \n                  .","journal-title":"J Burn Care Res"},{"issue":"4","key":"641_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1128\/AAC.34.4.614","volume":"34","author":"R Garraffo","year":"1990","unstructured":"Garraffo R, Drugeon HB, Dellamonica P, Bernard E, Lapalus P. Determination of optimal dosage regimen for amikacin in healthy-volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother. 1990;34(4):614\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"641_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329\u201332.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"641_CR31","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1542\/peds.103.4.e49","volume":"103","author":"JP Guignard","year":"1999","unstructured":"Guignard JP, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics. 1999;103(4):e49. \n                    https:\/\/doi.org\/10.1542\/peds.103.4.e49\n                    \n                  .","journal-title":"Pediatrics"},{"issue":"3","key":"641_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jac\/44.3.319","volume":"44","author":"MJ Weinbren","year":"1999","unstructured":"Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother. 1999;44(3):319\u201327. \n                    https:\/\/doi.org\/10.1093\/jac\/44.3.319\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"641_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/clinids\/14.2.458","volume":"14","author":"BA Boucher","year":"1992","unstructured":"Boucher BA, Kuhl DA, Hickerson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal-injury. Clin Infect Dis. 1992;14(2):458\u201363.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"641_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-199529010-00003","volume":"29","author":"L Jaehde","year":"1995","unstructured":"Jaehde L, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet. 1995;29(1):15\u201328.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"641_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bcp.12062","volume":"76","author":"JG Hasselt van","year":"2013","unstructured":"van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Optimizing drug development of anti-cancer drugs in children using modelling and simulation. Br J Clin Pharmacol. 2013;76(1):30\u201347. \n                    https:\/\/doi.org\/10.1111\/bcp.12062\n                    \n                  .","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0641-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T21:03:33Z","timestamp":1553288613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0641-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0641-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"23 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist with the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S\u00edlvia M. Illamola, Catherine M. Sherwin, and J. G. Coen van Hasselt have no conflicts of interest that are relevant to the content of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}